Tag: Chemotherapy
One-Cycle BE500P Seems Safe for High-Risk Early Testicular Cancer
Malignant recurrence rate was 1.3 percent at two years for one-cycle BE500P in high-risk early-stage disease
Adverse Events Decreased With Proton Chemoradiotherapy
Relative risks lower for 90-day adverse events of at least grade 3 and 2 compared with photon therapy
Antioxidant, Supplement Use May Worsen Breast Cancer Outcomes
Disease-free, overall survival poorer with vitamin B12 use before and during chemotherapy
Obesity May Up Cardiotoxicity Risk From Breast Cancer Therapy
Obesity independently associated with treatment-related cardiotoxicity in breast cancer patients
Continuing Full Induction Regimen Not Beneficial in Metastatic CRC
Maintenance therapy shows benefit versus observation in terms of PFS but not overall survival
SABCS: Addition of Tucatinib Ups Survival in HER2+ Metastatic Breast Cancer
In heavily pretreated patients, adding tucatinib versus placebo improves overall, progression-free survival
ASH: PET Helps Tailor Therapy in Limited-Stage DLBCL
Most patients had negative PET scan and completed one additional R-CHOP cycle without radiation
Endocrine Therapy Lowers QOL for Breast Cancer Patients
Effects of chemotherapy found to be more transient in comparison
Secondary Surgical Cytoreduction Not Superior in Ovarian Cancer
Addition of surgery prior to chemotherapy does not prolong overall survival in recurrent ovarian cancer
Gilteritinib Superior in Relapsed, Refractory FLT3-Mutated AML
Overall survival significantly longer, percentage of remission higher than with salvage chemotherapy
